Poor prognosis of mediastinal non-Hodgkin's lymphoma with an immature phenotype of CD2+, CD7 (or CD5)+, CD3−, CD4−, and CD8−

Abstract

Nine children with mediastinal non-Hodgkin's lymphoma (NHL) were treated according to our new regimen which is characterized by intensified therapy with highdose cytosine arabmoside (HDCA). After induction therapy with a combination of five drugs, such as vincristine, doxorubicin, cyclophosphamide, l-asparaginase, and prednisolone, intermediate dosages of methotrexate (MTX) (1 g/m2) and HDCA (1.5 g/m2 X 12 doses) were administered. All but one patient (88.9%) achieved complete remission and then received this intensified therapy. With a median follow-up period of 25.5 months, five patients are still in complete remission, but three patients have relapsed. From the phenotypic point of view, these relapsed patients showed only very immature T-cell differentiation antigens such as 0 2 and CD7 (or CD5). These results suggest that HDCA as intensified therapy for children with mediastinal NHL seems to be effective. However, for patients with an immature phenotype of T-lineage cells, more sophisticated regimens should be prepared.

CD7 promotes extramedullary involvement of the B-cell acute lymphoblastic leukemia line Tanoue by enhancing integrin β2-dependent cell adhesiveness

“…Clinically, the expression of CD7 correlates with a poor prognosis for acute myeloid leukemia (30)(31)(32)(33)(34)(35), non-Hodgkin's lymphoma (36) and B-lymphoblastic leukemia (37). Moreover, CD7 + , CD4 -, CD8acute lymphoblastic leukemia is reported to show poor clinical characteristics that involves extramedullary organs, including the mediastenum, skin, and CNS (38).…”

CD7+, CD5+, CD4−, CD8−, and CD3− T‐cell malignancy of the spleen after remission of invasive thymoma

“…An autopsy revealed non-Hodgkin's lymphoma, diffuse medium cell type with a T-cell phenotype of the spleen. The atypical lymphocytes in the peripheral blood expressed only CD7 and CD5 antigens, and not CD4, CD8, or CD3 antigens, suggesting prethymic-thymic T-cell leukemidymphoma, which has a poor prognosis [7]. Although it was not established when clonal proliferation occurred or whether the second neoplasm of the spleen occurred by chance, this is a unique case presenting immature phenotype T-cell malignancy of the spleen after remission of invasive thymoma.…”